Nevro Will Take On Spinal Cord Stim Leaders As Senza Is Stamped 'Superior'
This article was originally published in The Gray Sheet
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
You may also be interested in...
Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.
In the global pain management market, spinal cord stimulation (SCS) systems are expected to continue to be the fastest-growing segment with increasing competition among device manufacturers to develop innovative, targeted therapies. In this second article of a two-part series, we'll discuss the competitive landscape in the SCS market, the key players, emerging companies and their respective technologies.
Devices, or drug-delivery device, alternatives for pain control may provide at least a partial solution to the nation's opioid abuse epidemic, FDA Commissioner-nominee Scott Gottlieb said at his April 5 confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee.